focus -WSS

focus

author：leisure time 2025-09-03 11:57:34 - browse：686

From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

“I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： EPA limits use of carcinogenic gas for sterilizing medical devices

entertainment

WSS

How climate

FDA struggles to regulate food additives, sometimes for decades

FDA advisers back CAR

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

WuXi out of biotech trade group, U.S. and China relations to blame

Ebola: Gilead Sciences antiviral shows promise as new treatment

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

STAT Summit: Michael J. Fox on progress in Parkinson's research

Cancer drug shortages should be causing more outrage

Medicare coverage of Wegovy, once blocked, now looks possible

Wildfire smoke exposes gaps in outdoor worker protections

STAT Summit: Biotech founders on deal

Wildfire smoke exposes gaps in outdoor worker protections

Hospital price transparency does save money, advocate argues

Duchenne breakthrough therapy leaves behind pioneering families

The EU Joint Clinical Assessment needs to live up to its promise

explore

Why health workers in Gaza are injured or die at high rates

As AI in medicine takes off, can 'human in the loop' prevent harm?

Impact of Dobbs ruling felt at reproductive medicine meeting

President Biden's budget: Here's what you might have missed

STAT Summit: How a Chicago ER doctor tackles gun violence

As AI in medicine takes off, can 'human in the loop' prevent harm?

explore

hotspot

entertainment

focus